Infographic

Jun, 18 2024

Global Pharmacogenetics Testing in Psychiatry/Depression Market is Expected to Register a Healthy CAGR in the Forecast Period of 2024 to 2031

Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, and Psychotic Disorders), Product (Consumables, Instruments, and Software and Services), Test Type (Whole Genome Sequencing and Chromosomal Array Based Tests), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Patient Type (Adult, Geriatric, and Child), End User (Hospital and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others) - Industry Trends and Forecast to 2031.

Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-pharmacogenetic-testing-in-psychiatry-depression-market

Pharmacogenetics Testing in Psychiatry

 

Data Bridge Market Research

Office Number 402, Amanora Chambers, Magarpatta Road,

Hadapsar Pune – 411028.

Email: sales@databridgemarketresearch.com

Blog @ https://www.databridgemarketresearch.com/jp/news

 


Client Testimonials